用于癌症治疗的工程化T细胞。
Engineered T cells for cancer therapy.
作者信息
June Carl H, Maus Marcela V, Plesa Gabriela, Johnson Laura A, Zhao Yangbing, Levine Bruce L, Grupp Stephan A, Porter David L
机构信息
Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 8th Floor, Philadelphia, PA, 19104-5156, USA,
出版信息
Cancer Immunol Immunother. 2014 Sep;63(9):969-75. doi: 10.1007/s00262-014-1568-1. Epub 2014 Jun 19.
Abstract
It is now well established that the immune system can control and eliminate cancer cells. Adoptive T cell transfer has the potential to overcome the significant limitations associated with vaccine-based strategies in patients who are often immune compromised. Application of the emerging discipline of synthetic biology to cancer, which combines elements of genetic engineering and molecular biology to create new biological structures with enhanced functionalities, is the subject of this focused research review.
摘要
现在已经充分证实，免疫系统能够控制并消除癌细胞。在通常免疫功能受损的患者中，过继性T细胞转移有可能克服与基于疫苗的策略相关的重大局限性。合成生物学这一新兴学科在癌症领域的应用，即将基因工程和分子生物学元素结合起来以创造具有增强功能的新生物结构，是本重点研究综述的主题。
相似文献
1
Engineered T cells for cancer therapy.用于癌症治疗的工程化T细胞。
Cancer Immunol Immunother. 2014 Sep;63(9):969-75. doi: 10.1007/s00262-014-1568-1. Epub 2014 Jun 19.
2
T cell engineering as therapy for cancer and HIV: our synthetic future.作为癌症和艾滋病治疗手段的T细胞工程：我们的合成未来。
Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140374. doi: 10.1098/rstb.2014.0374.
3
Redirected T cells in cancer therapy.癌症治疗中的重定向T细胞。
Expert Opin Biol Ther. 2015;15(12):1667-70. doi: 10.1517/14712598.2015.1096340. Epub 2015 Oct 29.
4
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.合成免疫学：破解免疫细胞以拓展其治疗能力。
Annu Rev Immunol. 2017 Apr 26;35:229-253. doi: 10.1146/annurev-immunol-051116-052302.
5
Strategies to genetically engineer T cells for cancer immunotherapy.用于癌症免疫治疗的T细胞基因工程策略。
Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2.
6
Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.在T细胞免疫疗法的抗原受体设计中纳入链霉亲和素标签II。
Nat Biotechnol. 2016 Apr;34(4):430-4. doi: 10.1038/nbt.3461. Epub 2016 Feb 22.
7
Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.嵌合开关受体：用于改进癌症过继性T细胞疗法的转换技术
Immunotherapy. 2017 Dec;9(16):1339-1349. doi: 10.2217/imt-2017-0103.
8
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.使用肿瘤浸润性T细胞和基因工程化TCR-T细胞的T细胞过继性免疫疗法。
Int Immunol. 2016 Jul;28(7):349-53. doi: 10.1093/intimm/dxw022. Epub 2016 Apr 28.
9
CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.用于癌症治疗的嵌合抗原受体T细胞（CAR-T细胞）：当前设计与未来前沿
Methods Mol Biol. 2020;2086:1-10. doi: 10.1007/978-1-0716-0146-4_1.
10
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.基于 T 细胞的免疫疗法：过继细胞转移和检查点抑制。
Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.
引用本文的文献
1
Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives.过继性细胞疗法的新兴前沿领域：创新、挑战与未来展望。
Med Oncol. 2025 Jun 15;42(7):261. doi: 10.1007/s12032-025-02808-z.
2
Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities.追踪炎症状态以改善患者预后：当前方法、未满足的临床需求及机遇综述
Biotechnol Adv. 2025 Sep;82:108592. doi: 10.1016/j.biotechadv.2025.108592. Epub 2025 May 3.
3
Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity.修饰后的 FcγRI 表达使髓样细胞能够引发强烈的肿瘤特异性细胞毒性。
Elife. 2024 Jun 17;12:RP91999. doi: 10.7554/eLife.91999.
4
Advancements in Cell-Based Therapies for HIV Cure.基于细胞的艾滋病治疗方法的进展。
Cells. 2023 Dec 28;13(1):64. doi: 10.3390/cells13010064.
5
The U.S. Food and Drug Administration, the mechanism of action, and other considerations for cell-based therapy candidates.美国食品和药物管理局，细胞治疗候选物的作用机制和其他考虑因素。
Exp Biol Med (Maywood). 2023 Jul;248(13):1173-1180. doi: 10.1177/15353702231194250. Epub 2023 Aug 26.
6
Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling.基于细胞动力学/动态模型优化 CAR-T 细胞暴露的自体 CAR-T 细胞疗法的模型指导药物研发策略。
CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1577-1590. doi: 10.1002/psp4.13011. Epub 2023 Jul 28.
7
Smart Design of Nanostructures for Boosting Tumor Immunogenicity in Cancer Immunotherapy.用于增强癌症免疫治疗中肿瘤免疫原性的纳米结构的智能设计
Pharmaceutics. 2023 May 7;15(5):1427. doi: 10.3390/pharmaceutics15051427.
8
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.嵌合抗原受体 T 细胞疗法治疗 B 细胞血液系统恶性肿瘤后的复发机制及治疗策略。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221118413. doi: 10.1177/15330338221118413.
9
Systematic Review of Available CAR-T Cell Trials around the World.全球现有嵌合抗原受体T细胞（CAR-T）细胞试验的系统评价
Cancers (Basel). 2022 May 27;14(11):2667. doi: 10.3390/cancers14112667.
10
Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action.一种通过多种作用机制靶向CD20+癌症的计算机设计的利妥昔单抗/CD3 T细胞衔接器的生物活性验证
Antib Ther. 2021 Oct 22;4(4):228-241. doi: 10.1093/abt/tbab024. eCollection 2021 Oct.
本文引用的文献
1
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.间皮素特异性嵌合抗原受体 mRNA 修饰 T 细胞在实体恶性肿瘤中诱导抗肿瘤活性。
Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170.
2
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.抗体修饰的 T 细胞：CARs 在血液恶性肿瘤中占据主导地位。
Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.
3
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
4
Toxicity management for patients receiving novel T-cell engaging therapies.接受新型T细胞衔接疗法患者的毒性管理
Curr Opin Pediatr. 2014 Feb;26(1):43-9. doi: 10.1097/MOP.0000000000000043.
5
Chimeric antigen receptor therapy for cancer.嵌合抗原受体疗法治疗癌症。
Annu Rev Med. 2014;65:333-47. doi: 10.1146/annurev-med-060512-150254. Epub 2013 Nov 20.
6
Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer.阻断 TGF-β 信号通路极大地增强了 TCR 基因治疗癌症的疗效。
J Immunol. 2013 Sep 15;191(6):3232-9. doi: 10.4049/jimmunol.1301270. Epub 2013 Aug 12.
7
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.鉴定一种源自肌联蛋白的 HLA-A1 呈递肽作为工程化 MAGE A3 定向 T 细胞的交叉反应靶标。
Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.
8
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.采用合成生物学进行癌症免疫疗法中的过继细胞转移。
Immunity. 2013 Jul 25;39(1):49-60. doi: 10.1016/j.immuni.2013.07.002.
9
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.抗 PD-1 抗体治疗可显著增强基因修饰 T 细胞对已建立肿瘤的清除作用。
Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.
10
Perspective: assembly line immunotherapy.观点：流水线式免疫疗法。
Nature. 2013 Jun 27;498(7455):S17. doi: 10.1038/498S17a.
Zotero 插件